Intravenous immunoglobulin (IVIG) therapy is a highly effective and well-tolerated medical treatment primarily prescribed to individuals with compromised immune systems. IVIG therapy plays a crucial role in boosting the immune system in patients suffering from immunodeficiencies, autoimmune diseases, neurologic disorders, and certain infections.
Get IVIG Prior Authorization
However, determining the right dosage for patients based on the specific condition can be challenging, especially when it comes to maximizing the benefits of this treatment.
In this article, we will briefly outline the IVIG dosing guidelines for patients. In addition, we will address how IVIG therapy works, what factors are considered when calculating the IVIG doses, and at which rate IVIG is administered.
IVIG is a concentrated solution of immunoglobulins, also known as antibodies, given to patients intravenously (through a vein). These antibodies are extracted from the plasma of hundreds of donors, which later undergo rigorous screening and quality testing to ensure the final product is safe for the patients and free from foreign harmful substances.
How Does IVIG Work?
IVIG therapy provides a boost of antibodies that the patient may not naturally produce. In other cases, a patient might have antibodies but they are only present in insufficient quantities. IVIG benefits patients by strengthening their immune system, helping them fight off infection from foreign pathogens, and blocking the body from fighting against itself, as is the case with autoimmune conditions.
Personalized IVIG Dosing Guidelines
Healthcare providers follow an IVIG dosing guideline to calculate the doses, the infusion rate, and the frequency of dosage. Since each patient is unique, the doses of IVIG also vary in order to reduce the risk of adverse effects.
IVIG dosing guidelines help healthcare professionals ensure that each patient receives the appropriate amount of IVIG sufficient for managing their specific condition effectively.
Factors Considered for Determining the Right IVIG Dose
The dosage of IVIG can vary from patient to patient and mainly depends on several factors:
Ideal Body Weight (IBW)
The patient’s ideal body weight (IBW) is a critical factor in calculating the dose of IVIG. The IVIG dosage is often calculated in milligrams (mg) per kilogram (kg) of your body weight.
Generally, the higher your weight, the higher your IVIG dose will be. This is because larger individuals typically have a larger volume of blood and, consequently, require more IVIG to achieve the desired therapeutic effect. The weight-based calculation helps ensure that the treatment is personalized to your specific physiological characteristics.
Age is another important factor to consider when calculating the IVIG dosage. For instance, the dose of IVIG varies in adults and pediatric patients due to variations in their metabolism and immune system development. Pediatric patients often require dosage adjustments to ensure safety and treatment effectiveness.
Like age and weight, the medical condition that needs to be treated via IVIG treatment also affects the dosage range. For instance, if you have an immunodeficiency disorder (a condition in which your body either lacks essential antibodies or has insufficient antibodies), then you may receive IVIG in smaller doses, ranging from 400 to 600 mg/kg per month.
Conversely, if you have an autoimmune disease or any inflammatory condition such as Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), or myasthenia gravis (MG) and the purpose of the IVIG treatment is to block the immune system from attacking the body’s healthy cells, higher doses of IVIG are given, ranging from 1,000 to 3,000 mg/kg of body weight.
In some cases, patients with severe or aggressive conditions require higher or more frequent doses of IVIG to manage the disease symptoms.
Get IVIG Copay Assistance – Speak to a Specialist
Based on how well a patient responds to treatment over time, the IVIG dosage is adjusted. For instance, if you respond favorably to IVIG therapy and your condition stabilizes, your doctor may adjust the next IVIG doses accordingly. On the other hand, your healthcare professional could raise the IVIG dosage if your symptoms worsen or if your body becomes resistant to the medication.
Generally, in the beginning, the first two doses of an IVIG treatment are used as a baseline to assess the patient’s reaction to the medication and to minimize the potential for adverse effects.
The type of medical illness you have, and its intended course of therapy will determine how frequently IVIG is administered. According to the patient’s health status, specific condition, and responsiveness, IVIG is typically given at variable intervals, such as every three weeks, monthly, or on a different schedule.
For instance, if your illness necessitates more frequent infusions, you might have smaller IVIG doses more frequently to maintain steady therapeutic antibody levels. On the other hand, if you have a less frequent schedule, you might get higher doses of IVIG to make up for the gaps between infusions.
IVIG Dosing: Infusion Rate
Initially, IVIG infusions are started at a rate of 0.5 to 1 ml/kg/hour for the first 15 to 30 minutes. If no adverse reactions happen, the rate then increases every 15 to 30 minutes, up to a maximum of 3 to 6 ml/kg/hour.
Overall, IVIG therapy is a life-saving treatment option for individuals who have compromised immune systems, autoimmune diseases, neurologic disorders, and recurrent infections. The dosage of IVIG is influenced by several factors, such as weight, age, medical condition, treatment response, and frequency. Understanding these factors helps to determine the correct IVIG dosage and achieve effective results from this therapy.
- Arumugham, V. B., & Rayi, A. (2022). Intravenous immunoglobulin (IVIG). In StatPearls [Internet]. StatPearls Publishing.
- Rocchio, M. A., Hussey, A. P., Southard, R. A., & Szumita, P. M. (2013). Impact of ideal body weight dosing for all inpatients i.V. Immune globulin indications. American Journal of Health-System Pharmacy, 70(9), 751-752. https://doi.org/10.2146/ajhp110744
This information is not a substitute for medical advice or treatment. Talk to your doctor or healthcare provider about your medical condition prior to starting any new treatment. AmeriPharma Specialty Care assumes no liability whatsoever for the information provided or for any diagnosis or treatment made as a result, nor is it responsible for the reliability of the content.
AmeriPharma Specialty Care does not operate all the websites/organizations listed here, nor is it responsible for the availability or reliability of their content. These listings do not imply or constitute an endorsement, sponsorship, or recommendation by AmeriPharma Specialty Care.
This webpage may contain references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with AmeriPharma Specialty Care.
Dr. Samantha Kaeberlein, PharmD was born and raised in Canton, OH. She received her pharmacy degree from Northeast Ohio Medical University (NEOMED) in 2020. The most rewarding part of her job is providing medical guidance so patients can make informed, well-rounded decisions regarding their healthcare. Her areas of expertise are geriatrics and long-term care. In her free time, she enjoys spending time outdoors, reading, and hunting for the best cup of coffee in America.